Board of Directors

Dr. Menawat has been Novadaq’s President and CEO since April 2003. Previously, he held senior management positions at Cedara Software, Tenneco, Inc. and Hercules, Inc. His educational background includes a B.S. in Biology, University of District of Columbia, Washington, DC, Ph.D. in Chemical Engineering, from the University of Maryland, College Park, MD, and a Fellowship in Biomedical Engineering from the National Institute of Health, Bethesda, MD. He also earned an Executive MBA from the J.L. Kellogg School of Management, Northwestern University, Evanston, IL.

Mr. Davidson is a Managing Director of H.I.G. BioVentures and focuses on investment opportunities in the life sciences sector. Prior to joining H.I.G. in 2004, he was a Vice President with Ventures West with a focus on venture investing in life sciences companies. Mr. Davidson began his career with Eli Lilly Company, one of the largest global pharmaceutical companies. He spent a decade with Lilly in various management roles in the U.S. and Canada including business development, strategic planning, market research, and financial planning. After Lilly, he spent a year as the Vice President of Corporate Business Development at SYN-X Pharma. Mr. Davidson currently serves on the boards of Alder Biopharmaceuticals, HyperBranch Medical Technology, NeurAxon Inc., Novadaq Technologies Inc. and Tranzyme Pharmaceuticals. He served on the boards of Salmedix Inc. and GeminX Pharmaceuticals prior to Cephalon's acquisitions in June 2005 and April 2011 respectively. He also served on the board of Oncogenex Pharmaceuticals prior to their public listing. Aaron earned his MBA from Harvard Business School and a Bachelor of Commerce degree from McGill University.

Dr. Levy is the co-founder of QLT Inc., where she held several key positions, including President and CEO from 1995 to February 2002.  Under Dr. Levy's leadership, QLT recorded the strongest period of growth in company history and earned a reputation for achieving milestones, including FDA approval for Visudyne® therapy to treat wet AMD. Following her doctorate degree in immunology from the University of London, Dr. Levy was awarded an Industrial Professorship in the Department of Microbiology from the University of British Columbia and is the recipient of several honorary degrees. A fellow of the Royal Society of Canada and former President of the Canadian Federation of Biological Sciences, Dr. Levy has earned numerous awards and honors including an appointment as an Officer of the Order of Canada in 2001, the Female Entrepreneur of the Year for International Business in 1998, Pacific Canada Entrepreneur of the Year in 2000 and the Future of Vision Award from the Foundation Fighting Blindness in 2001. In 2002 she received, along with Dr. David Dolphin, the Friesen-Rygiel prize for medical research and the Prix Galien Canada research award. Along with Dr. Gustav Huber of Novartis, she was presented with the 2003 Helen Keller Prize for Innovation in Eye Care. In her honor, the Julia G. Levy Professorship in Ophthalmology Chair was created at Johns Hopkins Hospital Wilmer Eye Institute in 2004, the same year she was awarded the Lifetime Achievement Award from the British Columbia Biotechnology Association.  She is the author of many published scientific articles, a director of the Working Opportunity Fund (a Canada-based venture capital firm), and serves as a director with a number of public and private health care companies.

Dr. Shalowitz is Professor and Director of Health Industry Management at Northwestern University’s Kellogg School of Management; Professor of Preventive Medicine at the Feinberg School of Medicine and Visiting Professor of Health Industry Management at the Schulich School of Business at York University in Toronto. He co-founded, and is managing partner of, a 20-member primary care group in the suburban Chicago area, where he practiced internal medicine for 21 years. His honors include: Fellowship in the American College of Physicians, Fulbright Scholarship at the Schulich Business School, York University in Toronto (2004) and Fulbright Senior Specialist and Visiting Professorship at Keio University Medical School in Tokyo (2007). His recent coauthored books are: Strategic Marketing For Health Care Organizations: Building A Customer-Driven Health System (Jossey-Bass, 2008) and, Medical Innovation and Government Intervention (Taloustieto Oy, 2009). Dr. Shalowitz received his Sc.B. and M.D. degrees from Brown University and his MBA degree from Northwestern University. He completed post-graduate internal medicine training at Northwestern.